Systemic therapy for Asian patients with advanced BRAF V600 ‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan ( B‐CHECK‐RWD study)
Cancer Medicine · 2023-09 · 12 (17) · 17967-17980
DOI: 10.1002/cam4.6438 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 16.08.2023. Verfasst von Kenjiro Namikawa und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anti‐PD‐1‐based immunotherapy is considered a preferred first‐line treatment for advanced BRAF V600‐mutant melanoma. However, a recent international multi‐center study suggested that the efficacy of immunotherapy is poorer in Asian patients in the non‐acral cutaneous subtype. We hypothesized that the optimal first‐line treatment for Asian patients may be different.
Methods
We retrospectively collected data of Asian patients with advanced BRAF V600‐mutant melanoma treated with first‐line BRAF/MEK inhibitors (BRAF/MEKi), anti‐PD‐1 monotherapy (Anti‐PD‐1), and nivolumab plus ipilimumab (PD‐1/CTLA‐4) between 2016 and 2021 from 28 institutions in Japan.
Results
We identified 336 patients treated with BRAF/MEKi ( n = 236), Anti‐PD‐1 ( n = 64) and PD‐1/CTLA‐4 ( n = 36). The median follow‐up duration was 19.9 months for all patients and 28.6 months for the 184 pa tients who were alive at their last follow‐up. For patients treated with BRAF/MEKi, anti‐PD‐1, PD‐1/CTLA‐4, the median ages at baseline were 62, 62, and 53 years ( p = 0.03); objective response rates were 69%, 27%, and 28% ( p < 0.001); median progression‐free survival (PFS) was 14.7, 5.4, and 5.8 months ( p = 0.003), and median overall survival (OS) was 34.6, 37.0 months, and not reached, respectively ( p = 0.535). In multivariable analysis, hazard ratios (HRs) for PFS of Anti‐PD‐1 and PD‐1/CTLA‐4 compared with BRAF/MEKi were 2.30 ( p < 0.001) and 1.38 ( p = 0.147), and for OS, HRs were 1.37 ( p = 0.111) and 0.56 ( p = 0.075), respectively. In propensity‐score matching, BRAF/MEKi showed a tendency for longer PFS and equivalent OS with PD‐1/CTLA‐4 (HRs for PD‐1/CTLA‐4 were 1.78 [ p = 0.149]) and 1.03 [ p = 0.953], respectively). For patients who received second‐line treatment, BRAF/MEKi followed by PD‐1/CTLA‐4 showed poor survival outcomes.
Conclusions
The superiority of PD‐1/CTLA‐4 over BRAF/MEKi appears modest in Asian patients. First‐line BRAF/MEKi remains feasible, but it is difficult to salvage at progression. Ethnicity should be considered when selecting systemic therapies until personalized biomarkers are available in daily practice. Further studies are needed to establish the optimal treatment sequence for Asian patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Dermatology, Shinshu University, Matsumoto, Japan.
- Department of Dermatologic Oncology, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Kenjiro Namikawa, Yukiko Kiniwa, Junji Kato, Taku Maeda
Zitieren
APA
Namikawa, K., Ito, T., Yoshikawa, S., Yoshino, K., Kiniwa, Y., Ohe, S., Isei, T., Takenouchi, T., Kato, H., Mizuhashi, S., Fukushima, S., Yamamoto, Y., Inozume, T., Fujisawa, Y., Yamasaki, O., Nakamura, Y., Asai, J., Maekawa, T., Funakoshi, T., …, & Yamazaki, N. (2023). Systemic therapy for Asian patients with advanced BRAF V600 ‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan ( B‐CHECK‐RWD study). Cancer Medicine, 12(17), 17967-17980. https://doi.org/10.1002/cam4.6438
Vancouver
Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, et al. Systemic therapy for Asian patients with advanced BRAF V600 ‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan ( B‐CHECK‐RWD study). Cancer Medicine. 2023;12(17):17967-17980. doi:10.1002/cam4.6438
BibTeX
@article{Namikawa2023,
author = {Namikawa, Kenjiro and Ito, Takamichi and Yoshikawa, Shusuke and Yoshino, Koji and Kiniwa, Yukiko and Ohe, Shuichi and Isei, Taiki and Takenouchi, Tatsuya and Kato, Hiroshi and Mizuhashi, Satoru and Fukushima, Satoshi and Yamamoto, Yosuke and Inozume, Takashi and Fujisawa, Yasuhiro and Yamasaki, Osamu and Nakamura, Yasuhiro and Asai, Jun and Maekawa, Takeo and Funakoshi, Takeru and Matsushita, Shigeto and Nakano, Eiji and Oashi, Kohei and Kato, Junji and Uhara, Hisashi and Miyagawa, Takuya and Uchi, Hiroshi and Hatta, Naohito and Tsutsui, Keita and Maeda, Taku and Matsuya, Taisuke and Yanagisawa, Hiroto and Muto, Ikko and Okumura, Mao and Ogata, Dai and Yamazaki, Naoya},
title = {Systemic therapy for Asian patients with advanced BRAF V600 ‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan ( B‐CHECK‐RWD study)},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {17},
pages = {17967--17980},
doi = {10.1002/cam4.6438}
}
EUVIMED